article thumbnail

HeartBeam’s Artificial Intelligence Algorithm Combined with Vectorcardiography (VCG) Outperforms Expert Cardiologists in Detecting Arrhythmias

DAIC

a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced new study data demonstrating that HeartBeam AI combined with vectorcardiography (VCG) outperformed an expert panel of heart rhythm cardiologists in detecting atrial flutter. for EP panel). for EP panel).

article thumbnail

HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias

DAIC

In the study, HeartBeam AI with VCG demonstrated a 28% improvement over single-lead ECG in the detection of atrial flutter cases (sensitivity of 91.0% for single-lead ECG) without sacrificing the ability to identify those individuals without atrial flutter (specificity of 98.7% for VCG vs. 71.2% for VCG vs. 96.9%

article thumbnail

MP-470548-004 PERFORMANCE AND INTEROPERABILITY OF A VECTORCARDIOGRAM DEEP LEARNING ALGORITHM TO DETECT ATRIAL FLUTTER COMPARED TO ELECTROCARDIOGRAM ANALYSIS BY ELECTROPHYSIOLOGISTS

HeartRhythm

The representation of ECG vectors in X, Y, and Z axes in a vectorcardiogram (VCG) has shown diagnostic promise beyond single lead ECG (SL) analysis, with implications for novel ECG acquisition technologies. It is unclear how deep learning applied to VCG compares to physicians (EPs) for atrial flutter (AFL) detection.

article thumbnail

Atypical Atrial Flutter: Electrophysiological Characterization and Effective Catheter Ablation

Journal of Cardiovascular Electrophysiology

ABSTRACT Atrial flutter (AFL), defined as macro-re-entrant atrial tachycardia, is associated with debilitating symptoms, stroke, heart failure, and increased mortality. Atypical AFL is a heterogenous group of re-entrant atrial tachycardias that most commonly occur in patients with prior heart surgery or catheter ablation.

article thumbnail

Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation

DAIC

The trial will evaluate the outcomes of therapy provided with the FARAPULSE PFA System versus AADs, including device-or procedure-related adverse events, the rates of freedom from AF, atrial flutter, or atrial tachycardia, as well as AF burden – a measurement of the amount of AF an individual experiences. Circulation.

article thumbnail

Boston Scientific Receives FDA Approval for FARAPULSE Pulsed Field Ablation System

DAIC

In the written statement, he added, "A high bar has been set by performance of the system in clinical and commercial settings – where more than 40,000 patients have been treated to date – and we look forward to continuing to lead the way with this differentiated technology in the growing PFA space."

Ablation 111
article thumbnail

Cardiomatics guide: Analyzing arrhythmias made easy

Cardiomatics

In a world where technology reigns supreme, one of the most profound tools in medicine remains the irreplaceable electrocardiogram (ECG). As technology advances, so too does our ability to capture the heart’s rhythm with greater precision. AFIB/AFL – atrial fibrillation or atrial flutter episodes.